Last reviewed · How we verify

All participants (Aviane) — Competitive Intelligence Brief

All participants (Aviane) (All participants (Aviane)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral contraceptive (combined estrogen-progestin). Area: Contraception / Women's Health.

marketed Oral contraceptive (combined estrogen-progestin) Progesterone receptor, estrogen receptor Contraception / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

All participants (Aviane) (All participants (Aviane)) — Oregon Health and Science University. Aviane is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of ethinyl estradiol and levonorgestrel.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
All participants (Aviane) TARGET All participants (Aviane) Oregon Health and Science University marketed Oral contraceptive (combined estrogen-progestin) Progesterone receptor, estrogen receptor
Drospirenone Ethinyl estradiol Myo-inositol Drospirenone Ethinyl estradiol Myo-inositol AGUNCO Obstetrics and Gynecology Centre marketed Oral contraceptive with insulin sensitizer Progesterone receptor, estrogen receptor, inositol signaling pathway
Intermittent OC (EE/DROS) Intermittent OC (EE/DROS) University of North Carolina, Chapel Hill marketed Oral contraceptive Progesterone receptor, estrogen receptor
Etonogestrel/ethinyl estradiol vaginal ring Etonogestrel/ethinyl estradiol vaginal ring Andrea Roe, MD, MPH marketed Combined hormonal contraceptive Progesterone receptor, estrogen receptor
Continuous OC (EE/DROS) Continuous OC (EE/DROS) University of North Carolina, Chapel Hill marketed Oral contraceptive Progesterone receptor, estrogen receptor
Nomegestrol Acetate / Estradiol Nomegestrol Acetate / Estradiol University of Palermo marketed Combined oral contraceptive Progesterone receptor, Estrogen receptor
Drospirenone and Ethinyl Estradiol tablets Drospirenone and Ethinyl Estradiol tablets Hansoh BioMedical R&D Company marketed Combined oral contraceptive Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral contraceptive (combined estrogen-progestin) class)

  1. Bayer · 3 drugs in this class
  2. Organon and Co · 2 drugs in this class
  3. Teva Pharmaceuticals USA · 2 drugs in this class
  4. University of Colorado, Denver · 1 drug in this class
  5. Oregon Health and Science University · 1 drug in this class
  6. Helsinki University Central Hospital · 1 drug in this class
  7. Ironwood Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). All participants (Aviane) — Competitive Intelligence Brief. https://druglandscape.com/ci/all-participants-aviane. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: